|Bid||162.25 x 1200|
|Ask||179.31 x 800|
|Day's Range||172.20 - 174.42|
|52 Week Range||142.81 - 256.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||2.88 (1.64%)|
|1y Target Est||208.43|
Jun.21 -- Bloomberg's Drew Armstrong reports on the trend that's sweeping the medical aesthetics industry as the distributors of Botox, Dysport and Xeomin step up their efforts to sell cosmetic drugs to men. He speaks on "What'd You Miss?"
Allergan (AGN) is a specialty pharmaceutical company that develops various products through internal programs and in collaboration with other companies.
Bloomberg's Drew Armstrong reports on the trend that's sweeping the medical aesthetics industry as the distributors of Botox, Dysport and Xeomin step up their efforts to sell cosmetic drugs to men. He ...
Allergan’s (AGN) International Business segment includes revenue from both its Specialized Therapeutics portfolio and its General Medicines portfolio from outside the US markets.
Allergan’s (AGN) US General Medicines segment includes women’s health products, central nervous system products, anti-infective products, gastrointestinal products, and diversified brands.
As discussed earlier, Allergan’s (AGN) US Specialized Therapeutics segment includes revenue from the US sales of specialized products, including eye care products, medical esthetics products, dermatology products, neuroscience products, and urology products.
At Marina ManLand in the Los Angeles area, plastic surgeon Grant Stevens is injecting Botox into men as never before. “I’m doing more male surgery than ever before in my entire career,” Stevens said. ManLand is emblematic of a trend that’s sweeping the medical aesthetics industry as the distributors of drugs such as Botox, Dysport and Xeomin step up their efforts to sell cosmetic drugs to men.
As we discussed, Allergan (AGN) has restructured its business over the last few years, and now it reports its business revenue in three segments: US Specialized Therapeutics, US General Medicines, and International Business.
As discussed earlier, Allergan (AGN) reported a 2.8% rise in revenue to $3.7 billion during the first quarter of 2018 compared to revenue of $3.6 billion during the first quarter of 2017.
Wall Street analysts expect Allergan’s (AGN) adjusted EPS to be $4.10 on revenue of $3.9 billion during the second quarter, a 2.7% fall compared to $4.0 billion in the second quarter of 2017. No analysts have recommended “sells” on Allergan stock. Allergan’s stock price has fallen nearly 27.1% over the last 12 months but has risen ~5.0% in 2018 year-to-date.
Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.
The U.S. government is shifting its focus from accusing drug companies of overcharging to encouraging the marketplace to operate more competitively. On May 31, FDA Commissioner Scott Gottlieb, announced a draft guidance that will limit drug companies in delaying generics to market. Previously, generics needed to negotiate with branded firms.
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.
Allergan, whose director Patrick O'Sullivan will retire from the board in July, said its board will continue to have 12 members of which 10 are independent, following the changes. Freyman, who retired from Abbott in 2017, most recently served as executive vice president, finance and administration for the company since June 2015.
NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Stein ...
DUBLIN, June 14, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced that Thomas C. Freyman will join its Board of Directors effective immediately, as part of the company's ongoing board refreshment process. Mr. Freyman, a former Executive Vice President of Finance and Administration at Abbott Laboratories, brings nearly 40 years of healthcare industry and finance experience to Allergan's Board.
DUBLIN, June 13, 2018 /PRNewswire/ -- Allergan plc, (AGN), a leading global pharmaceutical company, today announced the release of new topline clinical trial data on Bimatoprost SR, the first-in-class sustained-release, biodegradable implant for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Bimatoprost SR is designed to lower IOP for at least 4 months, achieving clinical goals while freeing patients from daily eye drop regimens. In this first Phase 3 clinical study of 594 subjects with open-angle glaucoma or ocular hypertension, Bimatoprost SR reduced IOP by approximately 30 percent over the 12-week primary efficacy period, meeting the predefined criteria for non-inferiority to the study comparator, timolol.
Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.
Allergan Plc said on Monday its oral migraine drug met the main goal across all doses in a study, with a statistically significant reduction in monthly headache days in patients with episodic migraine. The treatment, atogepant, belongs to a class of migraine drugs also being developed by Eli Lilly and Alder Biopharmaceuticals that target a protein associated with pain signaling called calcitonin gene-related peptide (CGRP). Last month, the U.S. Food and Drug Administration approved Amgen Inc's CGRP treatment Aimovig, which is self injected monthly and will have a list price of $6,900 a year, or $575 a month.
As a micro-cap company, Axovant Sciences Ltd (NASDAQ:AXON) is naturally fraught with risks. The company is losing money and debt levels are elevated at 0.49 times equity. AXO-Lenti-PD is a gene therapy for treating Parkinson’s disease.
- Study meets primary endpoint for all doses and dose regimens - - Atogepant was well tolerated and there was no signal of hepatotoxicity with daily administration over 12 weeks - - Allergan will continue ...
Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.